Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Therapeutic Area

Otolaryngology

Therapeutic area intelligence for Otolaryngology with 6 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
6
Catalysts
0
Companies
2

Companies

Sanofi →
Sound Pharmaceuticals →

Assets

Itepekimab →
SPI-1005 →

Recent signals(6)

ClinicalJuly 28, 2026

Study Evaluates AAR's Reliability for Surgical Indication in Nasal Obstruction

The study assesses the reliability of Anterior Active Rhinomanometry (AAR) as a diagnostic tool for surgical indications in nasal obstruction, revealing a 48.5% concordance rate with clinical evaluations.

ClinicalJuly 7, 2026

Study on Gender Disparities in Voice Outcomes Post-Laryngectomy at UC Davis

A multi-site study aims to assess gender disparities in speech outcomes for total laryngectomy patients using TEP.

ClinicalJuly 1, 2026

SPI-1005 Trial for Meniere's Disease Evaluates Safety and Efficacy

A clinical trial is underway to assess the safety and efficacy of SPI-1005 in treating Meniere's disease symptoms.

ClinicalJune 29, 2026

SPI-1005 Trial for Adults with Cochlear Implants Shows Potential for Side Effect Management

The clinical trial aims to assess the safety and tolerability of SPI-1005 in adults receiving cochlear implants, focusing on side effects such as tinnitus and vertigo.

ClinicalJune 23, 2026

Sanofi and Regeneron Launch Phase 3 Study on Itepekimab for Chronic Rhinosinusitis

A Phase 3 extension study has been initiated to assess the long-term safety and tolerability of itepekimab in adults with inadequately controlled chronic rhinosinusitis with nasal polyps.

ClinicalJune 19, 2026

Study on Genetic Factors of Enlarged Vestibular Aqueducts and Hearing Loss

A clinical study is underway to analyze genetic factors associated with enlarged vestibular aqueducts, a condition linked to hearing loss.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

Meniere's Disease →
Voice Disorders →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.